drugset / Trial / NCT02894840

Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

NCT02894840

RandomizedParallel-groupDouble-blindPrevention

Summary

The study is aim to evaluate the safety and immunogenicity of one dose (15 μg HA per strain per dose) of the GPO seasonal trivalent inactivated split virion influenza vaccine (Tri Fluvac) in healthy adults aged 18 to 49 years over 90 days post-injection.

Timeline

Start
2015-11
Primary completion
2016-07
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tri Fluvac Vaccine 15 ug Intramuscular

Indications